Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma. - Wikidata - awgldk - TriplyDB

Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.

Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.

http://www.wikidata.org/entity/Q34110523

about

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers Osteosarcoma in Korean children and adolescents New small molecules targeting apoptosis and cell viability in osteosarcoma Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma.Prognostic value of IGF-1R expression in bone and soft tissue sarcomas: a meta-analysis.Association between exonic polymorphism (rs629849, Gly1619Arg) of IGF2R gene and obesity in Korean population.IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights Bone microenvironment signals in osteosarcoma development.Minireview: Were the IGF Signaling Inhibitors All Bad?A bispecific antibody targeting IGF-IR and EGFR has tumor and metastasis suppressive activity in an orthotopic xenograft osteosarcoma mouse model.Withaferin-A Induces Apoptosis in Osteosarcoma U2OS Cell Line via Generation of ROS and Disruption of Mitochondrial Membrane Potential.Targeting IGF1R pathway in cancer with microRNAs: How close are we ?IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.Advances in the Treatment of Pediatric Bone Sarcomas.

P2860

Q28082793-E68AA104-4022-4B61-8EB9-66F7885BB230 Q28083794-AF9654B8-E3B1-4EF7-A71A-977F76C2E3F2 Q28547760-F7EAEE2F-AFA2-40D4-96E9-8BDD8454A67E Q33850534-613507B5-7711-4D1C-8F4F-D6FC722AD845 Q35915343-60E37ABB-AF1D-4653-A6F6-B87D1DC90FC4 Q36223238-22260B01-51CE-4D7F-B459-41E048BB9FCA Q37615933-2D334F3C-25A0-418D-A884-0D4EEAF768CD Q38454980-CDE9109F-96B1-4969-8F0B-A90A5D2E150D Q38586367-79DA96FD-4B5E-4CD5-8101-44276817DA4E Q38651792-B9CA34A4-6B0E-49D9-B315-EE36E3B2DC4E Q38694216-926488AC-2FDE-47B0-BFDD-1D9B15D01D54 Q39371841-FDF307ED-609D-48FD-BFD4-F4D64F5DEEDA Q48262511-11F372C0-842B-496C-82D1-3E9542E3C200 Q50969326-5351D859-8948-483F-877C-B4F7B6FE10D3

P2860

Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.

http://www.wikidata.org/entity/Q34110523

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Insulin-like growth factor 1 r ...... ibody therapy in osteosarcoma.

@ast

Insulin-like growth factor 1 r ...... ibody therapy in osteosarcoma.

@en

Insulin-like growth factor 1 r ...... ibody therapy in osteosarcoma.

@nl

type

label

Insulin-like growth factor 1 r ...... ibody therapy in osteosarcoma.

@ast

Insulin-like growth factor 1 r ...... ibody therapy in osteosarcoma.

@en

Insulin-like growth factor 1 r ...... ibody therapy in osteosarcoma.

@nl

prefLabel

Insulin-like growth factor 1 r ...... ibody therapy in osteosarcoma.

@ast

Insulin-like growth factor 1 r ...... ibody therapy in osteosarcoma.

@en

Insulin-like growth factor 1 r ...... ibody therapy in osteosarcoma.

@nl

P1433

Q34110523-2D16D5DF-E04E-4CF4-BCA5-E1D12B4B452E

P1476

Q34110523-6D3955D8-C068-4B85-8CDF-46171B23A067

P2093

Q34110523-04BF55EC-3FE6-46D8-8958-4BBD45B6B858

Q34110523-148DC918-CD2A-4DAE-BBA9-CEF280E55587

Q34110523-541840FB-EFC8-4E54-BE1F-E7694440448A

Q34110523-563A8A96-C7DE-499A-9A3F-DD7A201F9CC6

Q34110523-58A8E26E-F03B-466B-BB5D-C609359F5A00

Q34110523-8DE29F3A-1617-42A0-800B-1F3DC1EDC3FD

Q34110523-9E10970E-D094-4590-8CEA-E48AEE634EB5

Q34110523-BAC8D1A4-303F-4E9F-8427-398382DCF66B

Q34110523-CD08C171-DB95-4504-B468-F9FDCBA9EB7C

Q34110523-CD5F9DF9-AF70-4DAD-AC37-3C3CC109EECE

P2860

Q34110523-0760F7CB-DE68-444F-958D-B1CCC2E60C0B

Q34110523-0A4F4DF0-CBE5-4172-84BA-2CFB5808EFE0

Q34110523-0EE6B1D0-84E5-4D30-ACF8-2D2CB585D2E7

Q34110523-16F6619F-1E03-4FBD-A990-21091E636613

Q34110523-171A1459-AF0E-4EFC-8F87-A57416074B3B

Q34110523-1AD9ADAA-9B85-4DD4-B771-6508908EB09D

Q34110523-1E27CF1A-F4F5-441D-A460-97C9CEDD7FC3

Q34110523-36C772A2-8A31-4FBF-BAC9-7D256D750933

Q34110523-3CAF770B-D190-4F77-859C-04FFB49B69C7

Q34110523-3DD94E02-5641-4187-9608-8DA8CEC7B187

P304

Q34110523-0DEE616F-5F68-4F16-8F7B-71D3FC3660A5

P31

Q34110523-2422847A-D384-4524-AA51-C2DE5ABE3F73

P356

Q34110523-F79C1CF4-A865-41D8-A12A-EC459B0ABC07

P407

Q34110523-854A2DF1-1035-475C-A065-57B35B18EBE0

P433

Q34110523-D0A492B8-4C99-4FC7-BC2B-7CA6C5626D60

P478

Q34110523-13681449-6DC1-4ABF-B065-04C2E048447C

P50

Q34110523-35D57EB9-5103-4079-B6C4-67C306158DE2

P577

Q34110523-DC5C9BF4-625A-4F54-8900-CD6122CF87DF

P5875

Q34110523-7499C0EF-DA97-4C7C-B389-C48EB934A28D

P698

Q34110523-F51F3A23-590E-4EFD-A75B-CD7B674BD740

P921

Q34110523-02C87249-01D6-4E50-AE95-F13D718F2E23

Q34110523-B4864A20-D1E0-4488-A277-BB5D883ED4B9

P932

Q34110523-524CB0E9-2A0A-42E8-88C0-F2FE282795A7

P356

JOURNAL.PONE.0106249

P1433

P1476

Insulin-like growth factor 1 r ...... ibody therapy in osteosarcoma.

@en

P2093

David Geller

http://www.w3.org/2001/XMLSchema#string

E Anders Kolb

http://www.w3.org/2001/XMLSchema#string

Jonathan Gill

http://www.w3.org/2001/XMLSchema#string

Kristofer Montoya

http://www.w3.org/2001/XMLSchema#string

Michael Roth

http://www.w3.org/2001/XMLSchema#string

Peter Houghton

http://www.w3.org/2001/XMLSchema#string

Pulivarthi Rao

http://www.w3.org/2001/XMLSchema#string

Rebecca Sowers

http://www.w3.org/2001/XMLSchema#string

Sajida Piperdi

http://www.w3.org/2001/XMLSchema#string

Yu Cao

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.

A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women

Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.

Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.

P304

e106249

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0106249

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Richard G Gorlick

P577

2014-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265174751

http://www.w3.org/2001/XMLSchema#string

P698

25170759

http://www.w3.org/2001/XMLSchema#string

P921

P932

4149550

http://www.w3.org/2001/XMLSchema#string